Eli Lilly announced additional results from its global, randomized, double-blind, placebo-controlled Phase III RANGE trial evaluating Cyramza (ramucirumab) in combination...
Latest analysis of the results from the DUO-E Phase III trial showed Imfinzi (durvalumab) plus platinum-based chemotherapy followed by Imfinzi plus Lynparza (olaparib) (Lynparza and Imfinzi arm) demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone
Eli Lilly announced that its Phase III RANGE study of Cyramza (ramucirumab) met its primary endpoint of progression-free survival (PFS),...
Until recently in the United States, no products were approved for second-line treatment of advanced urothelial carcinoma. On May 18, 2016, the U.S. Food and Drug Administration approved atezolizumab for the treatment...
Merck KGaA and Pfizer Inc announced completion of the submission of a supplemental Biologics License Application (sBLA) to the FDA for Bavencio (avelumab) for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) (Bladder Cancer).
The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.
Merck and Pfizer Inc. announced the Phase III JAVELIN Bladder 100 study met its primary endpoint of overall survival (OS)...
At the European Society for Medical Oncology (ESMO) 2017 Congress Phase III RANGE data from Eli Lilly and Company were...
Bristol Myers Squibb announced that CheckMate -274, a pivotal Phase III trial evaluating Opdivo (nivolumab) after surgery in patients with high-risk, muscle-invasive urothelial carcinoma met its primary endpoints of improving disease-free survival (DFS) versus placebo in both all randomized patients and in patients whose tumors express PD-L1 in at least 1% of cells (programmed death-ligand 1).
Merck Inc., and Eisai announced new investigational data demonstrating positive top-line results from the pivotal Phase III KEYNOTE-581/CLEAR trial (Study 307).